Feasibility of a Personalized SMS Intervention for Insomnia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05108194 |
Recruitment Status :
Recruiting
First Posted : November 4, 2021
Last Update Posted : April 25, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Insomnia Sleep Disorder | Behavioral: SMS Personalized Sleep Intervention | Early Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | All participants will enroll in the intervention after a two week assessment phase. |
Masking: | None (Open Label) |
Masking Description: | All participants will be enrolled in the intervention and all participants and study staff will be aware. |
Primary Purpose: | Treatment |
Official Title: | Feasibility of a Personalized Short Message Service Intervention for Insomnia |
Actual Study Start Date : | November 15, 2021 |
Estimated Primary Completion Date : | June 1, 2022 |
Estimated Study Completion Date : | June 1, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm 1: Intervention
Participants (N=50) who endorse insomnia will be followed for 8 weeks. All participants will be asked to download a separate app to passively monitor sleep that will inform the personalized messages. Participants will also be asked to respond to daily prompts in order to validate the passive sleep data. The study includes two phases: (1) a training and validation phase and (2) an intervention phase. During phase 1, participants' sleep habits and other behaviors will be monitored for two weeks in order to validate and optimize the SMS personalized sleep intervention (PSI). In phase 2, participants will be transitioned to the intervention phase of the study.
|
Behavioral: SMS Personalized Sleep Intervention
All participants will be enrolled in the intervention to evaluate the feasibility and acceptability of the SMS-PSI. After the data training and validation phase, participants will be provided with at least one and up to three daily text messages that offer users a specific strategy based on strategies from CBTi. All participants will have access to a "user dashboard", which is a web-app that includes personalized sleep-tracking information and the opportunity to customize their messaging. The person-level acceptability and adherence to the sleep strategies will be evaluated via self-report endorsement from daily diary and whether users added suggestions to their calendars. Both adherence and acceptability will be collected and integrated with the selection algorithm to optimize subsequent SMS suggestions. |
- Insomnia Severity Index [ Time Frame: 8 weeks ]Insomnia severity
- System Usability Scale [ Time Frame: 8 weeks ]Usability of the intervention
- PROMIS: Sleep related impairment [ Time Frame: 8 weeks ]Sleep-related functional impairment
- Flinders Fatigue Scale [ Time Frame: 8 weeks ]Fatigue
- Patient Health questionnaire 8 item [ Time Frame: 8 weeks ]Depression
- Difficulties in Emotion Regulation Scale [ Time Frame: 8 weeks ]Emotion regulation

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- clinical insomnia (defined by scoring ≥ 15 on the insomnia severity index)
Exclusion Criteria:
- under 18 y.o.
- unable to read or write in English
- do not own a Smart Phone

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05108194
Contact: Chelsey R Wilks, PhD | (314) 516-5383 | chelseywilks@umsl.edu |
United States, Missouri | |
University of Missouri-St Louis | Recruiting |
Saint Louis, Missouri, United States, 63121 |
Principal Investigator: | Chelsey R Wilks, PhD | University of Missouri, St. Louis |
Responsible Party: | Chelsey Wilks, Assistant Professor, University of Missouri, St. Louis |
ClinicalTrials.gov Identifier: | NCT05108194 |
Other Study ID Numbers: |
UMissouriSL |
First Posted: | November 4, 2021 Key Record Dates |
Last Update Posted: | April 25, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | De-identified participant outcome data will be made available to other researchers upon approval of home institution ethics approval. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) |
Time Frame: | One year after data collection is complete |
Access Criteria: | Approval from home institution internal review board |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Insomnia Sleep |
Sleep Initiation and Maintenance Disorders Sleep Wake Disorders Sleep Disorders, Intrinsic Dyssomnias |
Nervous System Diseases Mental Disorders Neurologic Manifestations |